HRAS and neoplasm: HRAS-mutant cell line derived xenograft models also exhibited tumour regression, irrespective of the mutation introduced, however WT mice did not, indicating its effects are restricted to oncogenic HRAS, potentially through reduction in angiogenesis and cell cycling (Gilardi et al., 2020).